| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

17-19 May 2021

BioEquity Europe Digital

13 May 2021

ORYZON to present new clinical data and corporate updates at international conferences in May and June

7 May 2021

ORYZON reports results and corporate update for quarter ended March 31, 2021

19 April 2021

ORYZON receives the INNOVATIVE SME seal from the Ministry of Science and Innovation

6 April 2021

ORYZON starts preclinical collaboration on autism with the Seaver Autism Center at Mount Sinai

29 March 2021

ORYZON enrolls first patient in PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder

24 March 2021

ORYZON publishes vafidemstat first-in-human clinical trial manuscript in CNS Drugs journal

13 April 2021

Business Roundtable on Health, Pharmas and Hospitals

28-30 April 2021

4th SACHS Annual Neuroscience Innovation Forum 2021

21 April 2021

Kempen Life Sciences Conference

Pagination

First page «
Previous page ‹
Page 19
Page 20
Page 21
Page 22
Current page 23
Page 24
Page 25
Page 26
Page 27
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel